Phase I trial of GlaxoSmithKline’s Ebola vaccine shows it is well tolerated No major adverse events were reported in an Ebola vaccine phase I trial involving 20 volunteers.…
Patient’s own glioblastoma cells used to treat tumour Hopes for a vaccine to tackle glioblastoma are bolstered by positive results from a phase I trial reported in Cancer Immunology and Immunotherapy.…
Review points to effectiveness of influenza vaccination Researchers have used “test-negative design” case-control studies to assess the effectiveness of seasonal influenza vaccine.…
Q&A: Ensuring vaccine safety is no easy task Patrick LF Zuber, group leader for global vaccine safety at the World Health Organization, talks about vaccine safety, the Ebola vaccine and new vaccines in the pipeline.…
Vaccine for human respiratory syncytial virus on the horizonA vaccine being developed to protect against human respiratory syncytial virus may offer hope in preventing this major cause of infant infection.…
Johnson & Johnson accelerates Ebola vaccine push Johnson & Johnson’s pharmaceuticals unit, Janssen, will invest US$200m in accelerating and expanding production of its Ebola vaccine.…
Vaccine evaluation process needs urgent reform The Joint Committee on Vaccination and Immunisation needs to be more open about how it decides which vaccines should be recommended for use in the UK.…
Phase II clinical trials for Ebola vaccine planned for early 2015Experts involved in the organisation of clinical research on Ebola vaccines intend to move to randomised controlled phase II trials in early 2015.…
Pneumococcal vaccine reduces antibiotic resistant infections in children by 62% The 13-valent pneumococcal conjugate vaccine (PCV13) has reduced the incidence of antibiotic resistant pneumococcal infections in children.…
Janssen and Novartis pick up 2014 Prix Galien awards Janssen and Novartis scooped prizes at the UK Prix Galien Awards for the first new drug for tuberculosis (TB) in 40 years and the first broadly protective meningitis B vaccine.…